fluphenazine has been researched along with amantadine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (71.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Mindham, RH | 1 |
| Gelenberg, AJ; Mandel, MR | 1 |
| Englert, LF; Ho, BT; McKenna, ML | 1 |
| Anstee, BH; Gaind, R; Mindham, RH; Rimmer, L | 1 |
| Baran, L; Maj, J; Sarnek, J; Sowińska, H | 1 |
| Czuczwar, SJ; Kleinrok, Z; Kozicka, M | 1 |
| Ang, L; Borison, RL; Davis, JM; Diamond, BI; Hamilton, WJ | 1 |
| Meier, J; Meyer, M; Pirovino, M; Schmid, M; Waldmeier, P | 1 |
| Ang, L; Borison, RL; Chang, S; Comaty, JE; Davis, JM; Dysken, M | 1 |
| Boettger, ML; McCarron, MM; Peck, JJ | 1 |
1 review(s) available for fluphenazine and amantadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for fluphenazine and amantadine
| Article | Year |
|---|---|
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Fluphenazine; Humans; Orphenadrine; Parkinson Disease, Secondary; Piribedil; Procyclidine | 1976 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Fluphenazine; Humans; Male; Orphenadrine; Parkinson Disease; Parkinson Disease, Secondary; Placebos; Schizophrenia | 1972 |
Treatment approaches in Gilles de la Tourette syndrome.
Topics: Amantadine; Benztropine; Clonidine; Fluphenazine; Haloperidol; Humans; Lithium; Tourette Syndrome; Trifluoperazine | 1983 |
New pharmacological approaches in the treatment of Tourette syndrome.
Topics: Adolescent; Adult; Amantadine; Benztropine; Child; Clinical Trials as Topic; Clonidine; Female; Fluphenazine; Haloperidol; Humans; Lithium; Male; Tourette Syndrome; Trifluoperazine | 1982 |
9 other study(ies) available for fluphenazine and amantadine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Catatonic reactions to high-potency neuroleptic drugs.
Topics: Adolescent; Adult; Amantadine; Catatonia; Dose-Response Relationship, Drug; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Parkinson Disease, Secondary; Schizophrenia | 1977 |
A potential amphetamine antagonist, adamantanamine derivative of fluphenazine.
Topics: Amantadine; Animals; Avoidance Learning; Dextroamphetamine; Fluphenazine; Male; Motor Activity; Rats | 1976 |
Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
Topics: Amantadine; Animals; Apomorphine; Blood Pressure; Body Temperature; Brain Chemistry; Catalepsy; Chlorpromazine; Dextroamphetamine; Disulfides; Dopamine; Female; Fluphenazine; Haloperidol; Humans; Imidazoles; Male; Methyltyrosines; Motor Activity; Norepinephrine; Oxotremorine; Parasympatholytics; Rats; Reflex; Reserpine; Spiro Compounds; Stereotyped Behavior | 1974 |
Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice.
Topics: Amantadine; Aminooxyacetic Acid; Amphetamine; Animals; Apomorphine; Baclofen; Dopamine; Electroshock; Female; Fluphenazine; gamma-Aminobutyric Acid; Haloperidol; Hydroxybutyrates; Levodopa; Male; Mice; Phenobarbital; Phenytoin; Receptors, Neurotransmitter; Seizures | 1980 |
[Malignant neuroleptics syndrome].
Topics: Adult; Amantadine; Baclofen; Cerebrospinal Fluid; Chromatography, Liquid; Cognition Disorders; Female; Fever; Fluphenazine; Humans; Intellectual Disability; Muscle Rigidity; Syndrome | 1984 |
A case of neuroleptic malignant syndrome successfully treated with amantadine.
Topics: Adult; Amantadine; Consciousness Disorders; Fluphenazine; Humans; Male; Malignant Hyperthermia; Muscle Rigidity; Schizophrenia, Paranoid; Syndrome; Thioridazine | 1982 |